Rocket Pharmaceuticals Securities Class Action Lawsuit: Important Lead Plaintiff Deadline Approaching

Purchasers of Rocket Pharmaceuticals securities may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement, thanks to a class action lawsuit filed against the company. The lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose key information about the effectiveness and safety of their RP-A501 treatment. The lead plaintiff deadline is August 11, 2025.

Key Takeaways:

• The lawsuit targets Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) for allegedly making false and/or misleading statements about their RP-A501 treatment.
• The Class Period spans from September 17, 2024, to May 26, 2025, during which time investors may have suffered damages.
• The lawsuit claims that defendants' public statements were materially false and misleading at all relevant times.
• A lead plaintiff is responsible for directing the litigation on behalf of other class members.
• The Rosen Law Firm, a global investor rights law firm, represents investors throughout the globe and has a track record of success in securities class actions.
• The firm has secured hundreds of millions of dollars for investors and has been recognized by Lawdragon, Super Lawyers, and ISS Securities Class Action Services.

Statistics:

• The lawsuit was filed on an unspecified date, but the lead plaintiff deadline is August 11, 2025.
• Over $438 million was secured for investors in 2019 alone.
• In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs' Bar by law360.
• The firm has recovered hundreds of millions of dollars for investors.

Sources:

• Rosen Law Firm, a global investor rights law firm
• law360
• Super Lawyers
• ISS Securities Class Action Services
• liability